C. difficile 위험도


Gonococcal urethritis, cervicitisRectal gonorrhea in femaleRectal gonorrhea in maleMild or moderate infectionSevere infectionLife-threatening infection0.5 g IV 1 dose0.5 g IV 1 dose1 g IV 1 dose1-2 g IV q8h2 g IV q6-8h2 g IV q4h

  • Age <1w 50 mg/kg IV q12h

  • Age 1-4w 50 mg/kg IV q8h

  • Age 1m-1y 50-180 mg/kg IV #4-6

  • BW >50 kg or age >12y Refer to adult dose (max 12 g/d)

CrCl >20CrCl ≤20No dose adjustment50% recommended dose at the recommended interval

General Information

Empiric therapy for:

  • Bacterial meningitis

  • Pneumonia (in combination with a macrolide)

  • Intra-abdominal infection including SBP

  • Musculoskeletal i.e. septic arthritis

  • Urinary tract infection

Monitor CBC with differential for treatment courses longer than 10 days.

Monitor renal function, and signs and symptoms of superinfection.


  • Injection site phlebitis/pain

  • Rash

  • Diarrhea

  • Vomiting


  • Cardiac dysrhythmia

  • Erythema multiforme

  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Agranulocytosis

  • Granulocytopenic disorder

  • Leukopenia

  • Neutropenic disorder

  • Pancytopenia

  • Hypersensitivity reaction

  • Warfarin- increased risk of bleeding

  • Cholera vaccine, live

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 1.5 hours

Biliary penetration: Moderate

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic


  • Dose reduction recommended in renal insufficiency.

  • Monitoring recommended for therapy lasting >10 days.

  • Urine glucose test utilizing copper reduction may induce false positive reaction.

  • Prefer ceftriaxone for CNS infection in renal failure.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.